Skip to main content
. 2011 Dec 12;122(1):253–266. doi: 10.1172/JCI59334

Figure 2. APNG confers resistance to GBM cells in vitro.

Figure 2

(A) Cell viability of A172 cells expressing EV, MGMT, APNG, or both MGMT and APNG in response to varying amounts of TMZ. (B) Representative Western blot of A172 cells stably expressing APNG, MGMT, or both under 100 μM TMZ. Cleaved PARP was used as a measure of apoptosis. Densitometry values (cleaved PARP relative to β-ACTIN) are shown below. (C) Western blot and cell viability in response to TMZ of site-directed APNG mutant R182A compared with WT APNG. (D) Western blot and cell viability in response to TMZ of site-directed MGMT mutant C145G compared with WT MGMT. (E) Activated cleaved caspase 3/7 levels of A172 cells expressing APNG, MGMT, or both. (F) Comet tail assay measuring DNA damage of A172 cells exposed to 100 μM TMZ. Comet tail length, indicative of less DNA damage, was reduced by expression of APNG and/or MGMT, but not their corresponding catalytic dead mutants. *P < 0.05, **P < 0.01.

HHS Vulnerability Disclosure